@Hertz WORST SERVICE EVER!!!!!! Nobody returns my phone calls and I get hung up on by your automated services!! HORRIBLE!!!!!! Will never rent a HERTZ CAR AGAIN!!!!!!!
@BananaRepublic@Barclays HORRIBLE CUSTOMER SERVICE with your new credit card spent 1.5 hours to try and understand fraudulent transactions on my card with ZERO RESOLUTION. Will never open another account!!!!
@MarriottBonvoy@Marriott - my Bonvoy account was hacked more than 2 weeks ago. I have called the Titanium Elite line more than 5 times without any response. Is there anything else that I can do? Please help.
#Sanofi reported that #Sarclisa (#Isatuximab) trial is first Phase 3 study to meet primary endpoint of minimal residual disease negativity in transplant-eligible patients with newly diagnosed #MultipleMyeloma https://t.co/PGtqlOGrVD
How I treat myeloma. Updated
#ASH21 edition algorithms. #ASH21VR @MayoMyeloma
I modified the first relapse algorithm to indicate that isatuximab can be used instead of daratumumab in certain regimens. @ASH_hematology
Isatuximab Plus RVd Improves MRD Negativity Rates in Transplant-Eligible, Newly Diagnosed Myeloma
More medical news at https://t.co/Z2xEnRpr3X
#Oncology#MedTwitter#MedEd#MedNews
https://t.co/UMGlJqFVhv
Isatuximab Plus RVd Improves MRD Negativity Rates in Transplant-Eligible, Newly Diagnosed Myeloma
For more up-to-date medical headlines, visit https://t.co/8ugyCPRjur
#MedicalNews#MedTwitter#MedEd#MedNews
https://t.co/a6cox0dDnU
#ASH21 Hartmut Goldschmidt—Addition of isatuximab to lenalidomide, bortezomib and dexamethasone improves MRD negativity at the end of induction for patients with newly-diagnosed, transplant-eligible multiple myeloma: results from the phase 3 GMMG-HD7 trial #mmsm
#ASH21 | Hartmut Goldschmidt @uniklinik_hd presents the GMMG-HD7 trial, powered to evaluate MRD neg after induction with isatuximab + VRd vs VRd in ND #myeloma. Response rate was similar regardless cytogenetic risk, but MRD data still needs to be analyzed #mmsm
Addition of Isatuximab to VRD As Induction Therapy for TE NDMM: The Phase III GMMG-HD7 Trial - 662 randomized with MRD negative by NGF 50% in Isa-RVd arm and 35.6% in RVd arm. No significant effect on safety. - Hartmut Goldschmidt #ASH21#mmsm#ASH21_MSKMM